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Although entrapment of nanoparticles of appropriate sizes at hair follicles has been clariﬁed, there is no
report on speciﬁc clinical application of this ﬁnding. Since sebaceous gland is associated with hair follicle,
we hypothesize that effective acne vulgaris treatment/prevention can be achieved by depositing anti-
acne agent in nanoparticle form at the hair follicles. Challenge of this strategy, however, lies at the
ﬁnding of effective anti-acne particles with minimal skin irritation. Here using cellulose-based nano-
particles as nano-reservoir and a-mangostin (an active component isolated from the edible Garcinia
mangostana Linn. fruit) as anti-acne agent, we prepare nanoparticles highly loaded with a-mangostin.
Ability of the obtained particles to sustained release a-mangostin into synthetic sebum is demonstrated.
The obtained mangostin particles are veriﬁed for their insigniﬁcant skin irritation through the two-week,
twice-daily open application test in 20 healthy human volunteers. Excellent entrapment and sustain-
ment of the mangostin nanoparticles at the hair follicles are elucidated in six human volunteers by
detecting the presence of a-mangostin at the roots of hairs pulled from the treated skin area. The 4-
week-randomized, double-blind, placebo-controlled, split-face study in 10 acne patients indicates sig-
niﬁcant improvement in acne vulgaris condition on the side twice daily applied with mangostin
nanoparticles.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Because nanoparticles of appropriate sizes and adequate me-
chanical stability can be pushed into hair follicles via a gear pump
mechanism (1, 2), release and migration of drugs from the drug-
loaded nanoparticles entrapped at the follicles, to sites associated
with the follicles, should theoretically be possible. Except in some
applications such as vaccine in which inﬂammation is desired,
presence of particles at hair follicles must not trigger skin irritation., Faculty of Science, Chula-
ok 10330, Thailand. Tel.: þ1
echarungruang).
rmacological Society.
. Production and hosting by ElseAt present, information on skin reaction caused by follicle entrap-
ment of nanoparticles is, however, lacking.
One of many causes of acne vulgaris is the proliferation of Pro-
pionibacterium acnes (P. acnes), a normal anaerobic ﬂora found in
sebaceous glands (3). Therefore, release and migration of drug
molecules from nanoparticles deposited at hair follicles to seba-
ceous glands should provide efﬁcient acne prevention and cure.
Mangosteen or Garcinia mangostana Linn. is a tropical plant in
Southeast Asia, belonging to the Clusiaceae family. Extract from the
mangosteen fruit (Gacinia mangostana extract or GME) has been
used for wound healing, eczema, skin infection and acne, for over a
hundred years (4, 5). a-Mangostin, the major active component in
GME (6, 7), has demonstrated anti-skin cancer (8), antioxidant (9,
10), anti-inﬂammatory (11), anti-allergy (12), antifungal (13) and
anti-P. acnes (14e16) activities.
The inexpensive ethyl cellulose-methyl cellulose (EC-MC)
polymer blend can be used to fabricate nanoparticles with excellentvier B.V. This is an open access article under the CC BY-NC-ND license (http://
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could be pushed into hair follicles of porcine skin (18). In this paper,
fabrication of EC-MC nanoparticles highly loadedwith a-mangostin
was carried out, and the obtained particle was characterized for
their a-mangostin loading capacity, particle size, in vitro release of
the loaded a-mangostin, and anti-P. acnes activity in cell culture.
Skin irritation of the particles was evaluated in 20 human volun-
teers using single application closed patch test and repeated
application open patch test. Hair follicle entrapment and oneweek-
retainment of the mangostin nanoparticles were evaluated in hu-
man volunteers' skin. Finally, acne vulgaris therapeutic effect of the
mangostin nanoparticles was preliminarily evaluated in 10 acne
patients using a 4-week randomized, double-blind, placebo-
controlled, split-face study. In addition to the demonstration of
acne treatment by depositing mangostin nanoparticles around the
sebaceous gland area, this study provides for the ﬁrst time the in-
formation on entrapment/retainment of nanoparticles at the hair
follicles of life human skin and also the skin reaction from such
entrapment. A protocol showing a simple analytical technique to
determine the presence of an interested material at the hair folli-
cles of human volunteers can also be found.
2. Material and methods
2.1. Fabrication of a-mangostin nanoparticle
Ethyl cellulose (EC, 45mg, viscosity 250e300 cp; ethoxy content
48%, SigmaeAldrich, Germany) and methyl cellulose (MC, 45 mg,
viscosity 400 cp; 1.60e1.90% degree of methoxy substitution, Sig-
maeAldrich) were dissolved in 85% (v/v) aqueous ethanol (15 mL),
and a-mangostin (94% a-mangostin, Welltech Biotechnology Co.,
Ltd., Thailand) solution (90 mg in 10 mL ethanol) was added. Then
water (75 mL) was slowly dropped into the obtained solution at the
rate of 2 mL/min with continuous mixing. The nanoparticles
formed were collected as suspension and ethanol was removed
using vacuum suction. Dry product was obtained by spray drying
(nozzle temperature of 130 C). Sample was subjected to scanning
electron microscopic (SEM, JSM-6400, JEOL, Japan), transmission
electron microscopic (TEM, JEM-2100, JEOL, Japan), dynamic light
scattering (DLS, Mastersizer S and Zeta sizernanoseries, Mulvern
Instruments, UK), and differential scanning calorimetric (DSC, DSC
204, Netzsch Group, Germany) analyses. Amount of a-mangostin in
the dry particles was rechecked by dissolving the particles in
ethanol, centrifugal ﬁltering the obtained solution through the MW
cut-off of 10,000 membrane to separated out the polymer, and
quantifying the a-mangostin in the ﬁltrate using UVeVis spec-
trometry (at 317 nm, the maximum absorption of a-mangostin in
ethanol) with the aid of a calibration curve. Loading of a-mangostin
in the obtained particles was calculated using equation as follow:
%Loading ¼ ([A]/[B])  100
[A] ¼Weight of loaded a-mangostin
[B] ¼Weight of a-mangostin-loaded particles.
The mangostin nanoparticle gel was prepared by dispersing
aqueous suspension of the mangostin particles into a gel base at the
ﬁnal a-mangostin concentrations of 0.3%, 0.6% and 1.2% (w/w). The
gel base was composed of water, xanthan gum, propylene glycol,
glycerin, allantoin, and preservatives (phenoxyethanol, methyl-
isothiozolinone and chlorphenesin).
2.2. Release of a-mangostin
Mangostin nanoparticles were dispersed in human synthetic
sebum (19) (ﬁnal concentration of 0.83 mg/mL) and kept at roomtemperature for 0, 1, 2, 4, 6, 8, 24 h. At each time point, the sus-
pension was centrifuged at 6440 g for 5 min. The obtained su-
pernatant was subjected to a-mangostin quantiﬁcation using UV
absorption spectrophotometry at 353 nm (maximum absorption of
a-mangostin in synthetic sebum) with the aid of a calibration curve
constructed from a-mangostin standards prepared in human syn-
thetic sebum. The solid nanoparticles from the centrifuge were re-
suspended in fresh synthetic sebum (same volume to the original
suspension before being centrifuge) and kept at room temperature
for analysis at the next time point. The process was repeated for the
accumulative release time points of 1, 2, 4, 6, 8, 24 h.
2.3. In vitro anti-P. acnes activity
Minimum inhibition concentration (MIC) and minimum bacte-
ricidal concentration (MBC) of mangostin nanoparticle against
P. acnes (ATCC 6919) were evaluated using the broth microdilution
technique (20). P. acnes was grown on brain heart infusion (BHI)
agar at 37 C for 48 h under anaerobic conditions. Single colony of
P. acnes was suspended in brain heart infusion (BHI) broth and the
turbidity was adjusted to match the 0.5 McFarland standard. The
test materials including aqueous suspension of mangostin nano-
particles, free a-mangostin solution in dimethylsulfoxide (DMSO),
streptomycin solution in sterile water and aqueous suspension of
unloaded nanoparticles, were serially diluted with BHI broth (2-
fold dilution) to the concentration range of 500e3.90 mg/mL, in
well plates. In the case of mangostin nanoparticle, the stated con-
centration range referred to the a-mangostin concentration. DMSO
used to aid the solubility of free a-mangostin was used at the ﬁnal
concentration of <0.2% v/v. Test suspensions were mixed with
P. acnes broth at 1:1 (v/v), thus the ﬁnal concentration of the test
materials in the well plates was in the range of 250e1.95 mg/mL.
The plates were then incubated at 37 C for 24 h under anaerobic
conditions. Then p-iodonitrotetrazoliumviolet solution (5 mL, 4 mg/
mL INT inwater) was added. The lowest concentration that showed
no red color was the MIC value. Then 3 mL of clear solution from
wells were spread on BHI agar plate and incubated at 37 C for 48 h
under anaerobic conditions and the P. acnes survival was visually
observed. The MBC was the lowest concentration of the test ma-
terial that showed no P. acnes survival.
2.4. Skin irritancy and a-mangostin sustainment at hair follicles
The study protocol was reviewed and approved by the Ethical
Review Committee of the Faculty of Medicine, Ramathibodi Hospi-
tal, Mahidol University, and the experiments were conducted ac-
cording to Declaration of Helsinki principles. Sixteen healthy female
and 4 healthymale volunteerswith the age range of 15e24 year olds
withnounderlying skin disease or skin lesion on the test area (upper
back, arm and shin) were recruited. All volunteers were older than
15 year olds, non-pregnant, and not breastfeeding. Volunteers
receiving immunosuppressive therapy, corticosteroids, antihista-
mines, and/or chemotherapy in the previous two weeks were
excluded. Informed consent was obtained from each participant.
Single application closed patch test and repeated open application
testwere carried outon samevolunteers. Irritancywas scoredby the
same dermatologist using a grading scale of 0e4 (Table 1).
2.4.1. Single application closed patch test
The test samples which included i) 0.3%, 0.6% and 1.2% (w/w)
mangostin nanoparticle gels, ii) gel base, iii) water, and iv) 2.5% SDS,
were applied as a patch on normal-appearing skin on the upper
back of test subjects under occlusion with a Finn chamber (8 mm
diameter, Finn Chamber, Epitest Ltd., Finland) for 24 h (21). After
the 24 h skin contact period, the patch was removed and signs of
Table 1
Grading scale for skin irritancy test.
Scale Description of skin response
0 No reaction
± Doubtful reaction: Glazed appearance of site or barely perceptible erythema
1 Weak reaction: Slight erythema or dryness across most of treatment site
2 Moderate reaction: moderate erythema, possibly spreading with barely perceptible edema at the margin; papules may be present
3 Strong reaction: moderate erythema with generalized edema
4 Severe reaction: severe erythema with severe edema, with or without vesicles, pustule or ulcer
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The test area was kept dry until the last day of the observation.
2.4.2. Repeated open application test (use test)
Repeated open application test was carried out for 1.2% man-
gostin nanoparticle gel, on the same group of volunteers who un-
derwent the single application closed patch test. The gel was
applied after shower on each volunteer's arm twice a day for 14
days at the same area, and the area was left uncovered. Volunteers
took showers normally without shielding the test area. The same
dermatologist observed signs of skin irritation on days 1, 2, 3, 7 and
14 post the ﬁrst application.
2.4.3. Hair follicle entrapment and retention
The study was carried out on six healthy volunteers. The 1.2%
mangostin nanoparticle gel was massaged (by hand) onto the
volunteer's skin around the shin area, at 0.25 mg/cm2 coverage of
a-mangostin on the skin, only once on day 0. Ten hairs in the test
area were pulled out daily (from day 0 to day 7) and subjected to a-
mangostin detection. The tested skin area was cleaned just prior to
the hair pulling by tape stripping using normal adhesive tape (Louis
Tape®, Samutprakarn, Thailand). Adhesive tape was pressed on the
skin and then removed from the skin, and this process was
repeated for 10 cycles at the same area. On day 0, the hairs were
pulled at 1 h after sample application. Presence of a-mangostin on
the hair samples was determined by detecting the ﬂuorescence
emission of a-mangostin with a confocal laser scanning ﬂuores-
cence microscope (CLFM, Nikon Digital Eclipse C1eSi equipped
with Plan Apochromat VC 100, MellesGriot Diode Laser and 85
YCA-series Laser, a Nikon TE2000-U microscope, a 32-channel-
PMT-spectral-detector and Nikon-EZ-C1 Gold Version 3.80 soft-
ware) using lex/lem of 405/425e585 nm. The obtained spectrum of
each pixel was unmixed into a-mangostin and human hair ﬂuo-
rescence components using chemometric analysis based on the
spectral database constructed from the ﬂuorescence spectra of a-
mangostin standard and the hair sample pulled from control skin
area (applied with gel base). Images were then constructed using
the obtained unmixed signals.
2.5. Acne vulgaris treatment
The study protocol was reviewed and approved by the Ethical
Review Committee of the Faculty of Medicine, Ramathibodi Hos-
pital, Mahidol University, and the experiments were conducted
according to Declaration of Helsinki principles. The anti-acne efﬁ-
ciency of mangostin nanoparticle gel (a-mangostin concentration
of 1.2% w/w) was compared with gel base (placebo) using a four-
week-randomized, double-blind, split-face study.
The test was carried out on 10 Thai patients (3 males and 7 fe-
males) of 15 year olds or older with non-inﬂammatory and in-
ﬂammatory acnes of5 lesions on their faces. Female patients were
non-pregnant, and not breastfeeding. All patients were free from
any topical or oral antibiotics administration for at least 8 weeks
and any oral retinoic acid derivatives administration for at least 1year, prior to the trial. All patients had neither other skin lesions nor
allergic history to a-mangostin.
One side of the patient's face was randomly assigned to receive
1.2% mangostin nanoparticle gel (treatment side) and the other side
was assigned to receive gel base (control side), twice a day (morning
and night, after shower) for 28 days. In order to help improving the
acne condition of the patients on both sides of their faces, prior to
every sample application, application of 2.5% benzoyl peroxide
cream to the whole face was carried out and then quickly washed
out thoroughly with water. The amount of mangostin nanoparticle
gel used was approximately 3 mL for each half face, which corre-
sponded to approximately 0.025mL/cm2 coverage of gel on the skin.
At the end of the treatment period (day 28 post ﬁrst application),
each patient's face was evaluated blindly by dermatologist.
Photographs of each patient's face were taken (VISIA Evolution,
Canﬁeld Scientiﬁc, Inc., Fairﬁeld, CT, USA) at baseline (immediately
prior to ﬁrst application) and on the 4th week (the end of the test).
Evaluation was carried out by 1) performing inﬂammatory lesion
count and 2) counting the numbers of inﬂamed and non-inﬂamed
acnes and using the obtained numbers to calculate acne severity
index (ASI) from the following equation (22).
ASI ¼ papules þ (2  pustules) þ (comedones/4)
2.6. Statistical analysis
The McNemar statistical analysis was used in the irritancy ex-
periments, paired t-test and McNemar statistical analyses were
used to analyze acne treatment results.
3. Results
3.1. Mangostin nanoparticles
When water was slowly added to the ethanolic solution con-
taining EC, MC and a-mangostin, cloudy suspension was observed
(Fig. 1A). SEM and TEM analysis of the suspension indicated
spherical nanoparticles with the dry size of 300e500 nm (Fig. 1 B,
C), and DLS analysis indicated the hydrodynamic diameter of
436.0 ± 11.5 nm (polydispersity index of 0.111 ± 0.024). Neither
mangostin precipitate nor crystal was observed in the suspension.
The loading of a-mangostin in the obtained particles was
41.90 ± 0.79%. The obtained mangostin nanoparticles showed
different phase change behavior from those of the unloaded par-
ticles and the free a-mangostin (Fig. 1D), a sustained a-mangostin
release in human synthetic sebum (Fig. 2), and in vitro anti-P. acnes
activity (Table 2).
3.2. Skin irritancy test
3.2.1. Single application closed patch test
None of the 20 volunteers dropped out or missed follow-up
visits throughout the experiment period. McNemar statistical
Fig. 1. (A) Photographs of aqueous suspension of mangostin nanoparticles. (B) SEM and (C) TEM images of the mangostin nanoparticles. (D) Thermograms of mangostin nano-
particles, empty particles and free a-mangostin.
Table 2
The minimal inhibition concentration (MIC) and minimal bactericidal concentration





Mangostin nanoparticles in water 15.625a >250a
Free a-mangostin in DMSO 15.625 15.625
Free a-mangostin in water >250 >250
Unloaded nanoparticles in water >250 >250
Streptomycin in water <1.95 <1.95
a The reported numbers indicate the a-mangostin concentration.
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mangostin nanoparticle gel (0.3, 0.6 and 1.2%) gave similar skin
irritation level to the positive control (2.5% sodium dodecyl
sulfate or SDS), with the P-value > 0.05, while the gel base did
not induce similar level of irritation (Supplementary Table S1).
However, the degree of irritancy decreased quickly. At 24 h
post patch removal, all three mangostin nanoparticle gels
showed lower skin irritation level than the positive control, i.e.,
a faint erythema (grade 0.5) was observed in only one volun-
teer (0.5%) for both the 0.3 and 0.6% gels, and two volunteers
(10%) for the 1.2% gel. At 48 h post patch removal, the erythema
completely disappeared for the 0.3% and 0.6% gels while the
faint erythema (grade ¼ 0.5) was observed in one volunteer
(5%) for the 1.2% mangostin nanoparticle gel (Supplementary
Table S1). McNemar statistical analysis indicated that at 24
and 48 h post patch removal, all three mangostin nanoparticle
gels gave different skin irritation level from the positive control
with the P < 0.05.
3.2.2. Repeated open application test (use test)
The two-week repeated open application test of 1.2% mangostin
nanoparticle gel on 20 volunteers revealed that the gel did not
cause any skin irritation to 19 (95%) volunteers. Only 1 volunteer
(5%) developed a doubtful positive result on day 2, but the irritation
response disappeared on day 3 and no sign of irritation was
observed again. The observation on day 14 (last day of the study)
revealed that none of the volunteers developed skin irritant signs
such as erythema, itching, edema, burning, vesicle or pustule
(Supplementary Tables S2 and S3).Fig. 2. Release of a-mangostin from mangostin nanoparticles in human synthetic
sebum at 37 C. Mangostin nanoparticles were suspended in synthetic sebum at the
ﬁnal concentration of 0.83 mg/mL and at an indicated time point the particles were
separated out from the sebum by centrifugation and the sebum was then subjected to
a-mangostin quantiﬁcation by UV spectroscopy. The particles were resuspended in
fresh sebum of the same volume for further monitoring of the release using the same
process. Data are shown as means ± SD.3.3. Entrapment and sustainment at hair follicles
No a-mangostin was detected on all control hair samples (hairs
pulled from skin area applied with gel base, negative control).
Percentages of hairs containing a-mangostin at their roots were
93.3 ± 16.3, 73.3 ± 17.5, 59.2 ± 20.1, 41.7 ± 29.9 and 38.3 ± 19.4, for
hairs pulled out from the treated skin area (the area applied with
1.2% mangostin nanoparticle gel) on day 0, 1, 2, 4, and 7 post single
application, respectively (Supplementary Fig. S1 and Table S4). The
treated skin area showed no sign of skin irritation.
3.4. Acne treatment
None of the 10 acne patients missed the follow-up visits
throughout the 4-week split face study. The patients were 2 males
and 8 females with an age average of 23.60 ± 3.13 year olds. All
patients had had acne for 5.70 ± 3.02 years. At the start, there was
no signiﬁcant difference between the two sides of patient faces in
term of the acne severity index (ASI) (P ¼ 0.71) and the inﬂam-
matory lesion count (P ¼ 0.81) (Fig. 3A and B). Comparing between
the values at baseline and the values at 4 weeks post ﬁrst appli-
cation, the paired t-test analysis indicated that the side applied
with 1.2% mangostin nanoparticle gel (treated side) showed
signiﬁcantlymore decrease in both the ASI value (P¼ 0.042, Fig. 3A)
and the inﬂammatory lesion (P ¼ 0.035, Fig. 3B) than the side
applied with gel base (control side) (Fig. 3C).
4. Discussion
The slow addition of water (anti-solvent) into the ethanolic
solution containing a-mangostin and polymers (EC and MC),
allowed the self-assembling of the water insoluble materials, EC
and a-mangostin, into nanoparticles. The water-soluble MC poly-
mers were probably entangled with EC and some were incorpo-
rated into the forming nanoparticles (17). The obtained water
dispersible particles could be dry by freeze-drying or spray-drying
with no change in particle morphology if the temperature of the
Fig. 3. Evaluation of mangostin nanoparticle effect on acne using the split face study: Graphs showing acne severity index (A) and inﬂammatory lesion count (B) at baseline (0
week) and after a 4-week treatment (statistical differences were analyzed by a paired t-test and are indicated with *; Picture of one representative acne patient who underwent the
4-week split face study in which gel base (control) and mangostin nanoparticle gel were applied twice daily for 28 days (C).
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temperature of the EC polymer used) (23). As observed by SEM,
TEM and DLS, spherical mangostin nanoparticles with the size of
around 400 nm (Fig. 1B and C) were obtained and neither unen-
capsulated a-mangostin precipitate nor crystals was observed. The
obtained particle size was optimal for the follicular penetration
reported earlier (2). The thermogram of mangostin nanoparticles
showed neither melting peak of crystalline a-mangostin at 184 C
nor characteristic peaks of unloaded polymeric particles at 130, 185
and 226 C (corresponded to glass transition, melting and decom-
position) (Fig. 1D), indicating that the encapsulated a-mangostin
molecules interacted well with the EC-MC polymer matrix.
Therefore, the molecular arrangement of mangostin nanoparticles
was concluded as an amorphous or disordered-crystalline phase of
the a-mangostin solid solution in the EC-MC polymer matrix.
In vitro anti-P. acnes activity was observed for the obtained man-
gostin nanoparticle (Table 2). The free mangostin in water showed
no activity even at 250 mg/mL. This agreed well with the low water
solubility of a-mangostin. The mangostin nanoparticles in water,
however, showed similar MIC value (15.625 mg/mL) to that of the
free mangostin in DMSO. Since the experiment was carried out in
aqueous bacterial culture environment, we speculated that the
mangostin nanoparticles probably attached well to the surface of
the P. acnes, and direct release of a-mangostin from the particles to
the P. acnes could take place (release of a-mangostin from the
particles into the water medium was prevented by the low solu-
bility of the material). This resulted in lower MIC value for theaqueous mangostin particle suspension as compared to that of the
free a-mangostin in water. The sustained release of a-mangostin
into P. acnes and also the limited surface area of the bacteria,
nevertheless, also disallowed the built up of high concentration of
a-mangostin on the bacteria. This permitted the halt of bacterial
growth, however, prevented the bacteria from being killed even
when the concentration of the mangostin nanoparticles was
increased to 250 mg/mL. It should be noted here that this aqueous
environment of P. acnes culture condition is quite different from the
actual skin residence of P. acneswhere the bacteria are surrounded
by hydrophobic sebum secreted from the sebaceous gland.
The in vitro a-mangostin release character of the particles was
acquired using human synthetic sebum as a release medium. This
was because not only a-mangostin was soluble in the synthetic
sebum, but also we wanted to mimic the sebum rich environment
at the targeted site of the particles in the intended application.
Sustained release of a-mangostin from the particles was observed
(Fig. 2). The release rate was fast and constant at the beginning;
approximately 55% a-mangostinwere released during the ﬁrst 10 h.
Then the release was slowing down; approximately 10% a-man-
gostin was released during h 10 to h 24. The rate decreased further
and stayed constant from day 2 to day 7; approximately 25% a-
mangostin were released during the last 6 days. This sustained
release character agreed with the good interaction between a-
mangostin and polymer matrix discussed above. The release likely
occurred through a diffusion-controlled mechanism in which the
high concentration gradient at the beginning corresponded well
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that the release rate could be adjusted by changing the loading
content of a-mangostin in the particles. This is because the release
mechanism is diffusion controlled, and thus is directly affected by
the concentration gradient between the inside and the outside of
the particles. The obtained release character in which 50% of the
materials are released at a constant rate during the ﬁrst 8 h should
fulﬁll our purpose of harming the P. acnes as much as possible at the
non-irritating concentration. The slower release of the other 50% of
the material is also useful for the P. acnes prevention effect and
some anti-inﬂammatory effect at the hair follicles.
Aqueous suspension of the mangostin nanoparticles was too
runny to apply onto the skin without dripping, thus aqueous gel of
the suspension was prepared. The 14-day-repeated open applica-
tion test in 20 human volunteers indicates that the 1.2% mangostin
nanoparticle gel can be used daily on human skin under normal
condition with low risk of skin irritation. The material, however,
may cause mild and temporary skin irritation if it is applied as a
closed patch. We further investigated the follicle penetration efﬁ-
ciency of the mangostin nanoparticles on six human volunteers.
Interestingly, 93.3 ± 16.3% hairs pulled at 1 h post mangostin
nanoparticle gel application showed obvious presence of a-man-
gostin on their roots. Since the skinwas clean by tape striping prior
to the hair pulling, the detection of a-mangostin on the hair roots
deﬁnitely indicated a presence of the material in the hair follicles.
At 24 h post the single application and after one normal shower,
73.3 ± 17.5% of the hairs pulled from the treated area showed
obvious a-mangostin presence. The numbers of hair with detect-
able a-mangostin decreased with increased post application time
and this was likely to be from i) tissue absorption of the released a-
mangostin, and ii) elimination of the entrapped particles from the
follicles (probably by natural hair growth and continuous sebum
secretion). Nevertheless, 38.3 ± 19.4% of hairs pulled out on day 7
still showed a-mangostin presence. Therefore, it was concluded
that mangostin nanoparticle entrapment into the hair follicles
could be achieved easily, and the entrapped material showed good
retainment. More importantly, no skin irritationwas at all observed
in six volunteers. This indicated that the presence of mangostin
nanoparticles inside the hair follicles did not cause skin irritation.
The ability of 1.2% mangostin nanoparticle gel to cure acne was
evaluated in 10 acne patients through a 4-week split face study,
with gel base as a control. It should be noted here that, un-
encapsulated a-mangostin could not be prepared into an alcohol
free aqueous gel for use as a control because the material is water
insoluble. In order to help improving the acne condition on both
sides of the patients' faces, prior to every sample application, the
2.5% benzoyl peroxide cream was used during the face wash step.
The cream was then completely washed off before the gel appli-
cation. And indeed, both the control and the treatment sides
showed improvement on both the ASI and inﬂammatory lesion
counts. Signiﬁcantly better improvements (40%more improvement
in ASI and more than 50% improvement of inﬂammatory lesion
counts comparing to the control) were clearly observed on the side
of the faces treated with mangostin nanoparticle gel (Fig. 3). These
double improvements in clinical signs of the mangostin
nanoparticle-treated side over those of the control side satisﬁed
our preliminary clinical trial, thus should encourage the clinical use
of the mangostin nanoparticles in acne treatment.
5. Conclusion
Here a-mangostin was encapsulated into the EC-MC nano-
particles, and the obtained 400 nm spherical nanoparticles with
50% a-mangostin loading content were veriﬁed for their anti-
P. acnes activity in cell culture. In vitro sustained release of a-mangostin from the particles into synthetic sebum was observed
and this agreed well with the good molecular interaction between
a-mangostin and polymeric matrix implied by the thermogram of
the particles. Evaluation of the obtainedmangostin nanoparticles in
20 human volunteers by a 2-week-repeated application open patch
test revealed insigniﬁcant skin irritation. Excellent hair follicle
entrapment of the obtained mangostin nanoparticles and sustain-
ment of the material were veriﬁed through a one-week experiment
on the skin of six human volunteers, using a hair pulling and a-
mangostin detection at the hair's root strategy. Finally, acne vul-
garis therapeutic effect of the obtained mangostin nanoparticles
was observed in 10 acne patients using a 4-week randomized,
double-blind, placebo-controlled, split-face study. The satisﬁed
preliminary clinical trial obtained here veriﬁes a new way to treat
and also prevent acne via the deposition of the 400 nm mangostin
nanoparticles at the hair follicles.
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